异丁基丙二酸二甲酯 | 39520-24-6

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 异丁基丙二酸二甲酯
• 英文名称: Isobutylmalonsaeure-dimethylester
• 英文别名: dimethyl 2-isobutylmalonate；dimethyl isobutylmalonate；isobutyl-malonic acid dimethyl ester；Isobutyl-malonsaeure-dimethylester；3-Methyl-butan-dicarbonsaeure-(1.1)-dimethylester；dimethyl 2-(2-methylpropyl)propanedioate
• CAS: 39520-24-6
• 化学式: C₉H₁₆O₄
• 分子量: 188.224
• InChiKey: GAZFDPSEEIVCEX-UHFFFAOYSA-N

物化性质

• 沸点：
  213 °C (lit.)
• 密度：
  1.012 g/mL at 25 °C (lit.)
• 闪点：
  208 °F
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2917190090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	Dimethyl Isobutylmalonate 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	39520-24-6

Section 1 - Chemical Product MSDS Name:Dimethyl Isobutylmalonate 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
39520-24-6	Dimethyl Isobutylmalonate	98%	254-490-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 39520-24-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: colorless to light yellow
Odor: fruity odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 211 deg C @ 763 mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H16O4
Molecular Weight: 188.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat.
Incompatibilities with Other Materials:
Acids, bases, oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 39520-24-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Dimethyl Isobutylmalonate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 39520-24-6: No information available.
Canada
CAS# 39520-24-6 is listed on Canada's NDSL List.
CAS# 39520-24-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 39520-24-6 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：无色透明的液态物质。

反应信息

• 作为反应物：
  描述：

  异丁基丙二酸二甲酯 在 对甲苯磺酰叠氮 、 sodium hydride 作用下， 生成 Azidoisobutylmalonsaeure-dimethylester
  参考文献：
  名称：

  Frank, Juergen; Stoll, Gerhard; Musso, Hans, Liebigs Annalen der Chemie, 1986, # 11, p. 1990 - 1996

  摘要：

  DOI：
• 作为产物：
  描述：

  甲醇 、 2-(2-甲基丙基)-丙二酸 在 硫酸 作用下， 生成 异丁基丙二酸二甲酯
  参考文献：
  名称：

  Marshall, Recueil des Travaux Chimiques des Pays-Bas, 1932, vol. 51, p. 234

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE HÉTÉROCYCLIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016022312A1

  公开（公告）日：2016-02-11

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开内容通常涉及能够抑制AAK1（适配器相关激酶1）的化合物、包含该化合物的组合物以及抑制AAK1的方法。
• Ligand dependence of molybdenum-catalyzed alkylations. Molybdenum-isonitrile complexes as a new class of highly reactive alkylation catalysts
  作者：Barry M. Trost、Craig A. Merlic

  DOI：10.1021/ja00182a018

  日期：1990.12

  generates the most effective molybdenum catalysts known to date. The reactive catalyst proved to be Mo(RNC) 4 (CO) 2 . With this new catalyst, a much broader range of substrates can be employed including many that failed or reacted very poorly by using molybdenum hexacarbonyl. The regioselectivity also differs from that obtained with molybdenum hexacarbonyl. The stereochemistry of the reaction proceeds with

  已经制备了一系列带有-α-二亚胺、N,N'-二亚芳基乙二胺和异腈配体的钼配合物，并评估了它们通过使用乙酸烯丙酯，尤其是烯丙基砜催化烷基化的能力。与bpyMo(CO) 4 相比，(bpy)Mo(CH 3 CN)(CO) 3 被证明是一种非常有效的催化剂。将异腈配体添加到六羰基钼上可产生迄今为止已知的最有效的钼催化剂。反应性催化剂被证明是Mo(RNC) 4 (CO) 2 。使用这种新催化剂，可以使用更广泛的底物，包括许多因使用六羰基钼而失效或反应非常差的底物。区域选择性也不同于使用六羰基钼获得的区域选择性。即使在产生与六羰基钼的非对映异构体混合物的条件下，反应的立体化学也以非常干净的净保留构型进行。提出了一种解释看似不同的催化剂复合物的机械原理
• [EN] BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS BIOACTIFS POUR LE TRAITEMENT DU CANCER ET DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：PONIARD PHARMACEUTICALS INC

  公开号：WO2009139834A1

  公开（公告）日：2009-11-19

  The invention provides bioactive compounds for the treatment of various malconditions such as cancer and neurodegenerative diseases including Alzheimer's disease. The chemical compounds as disclosed herein are found to show bioactivity in bioassays related to these conditions. Pharmaceutical compositions, combinations and methods of synthesis are provided, as are methods of using the compound, compositions and combinations in the treatment of the diseases.

  这项发明提供了用于治疗各种恶性疾病，如癌症和包括阿尔茨海默病在内的神经退行性疾病的生物活性化合物。本文所披露的化合物在与这些疾病相关的生物测定中显示出生物活性。提供了药物组合物、组合物和合成方法，以及使用该化合物、组合物和组合物治疗这些疾病的方法。
• Palladium‐Catalyzed Atom‐Transfer Radical Cyclization at Remote Unactivated C(sp ³ )−H Sites: Hydrogen‐Atom Transfer of Hybrid Vinyl Palladium Radical Intermediates
  作者：Maxim Ratushnyy、Marvin Parasram、Yang Wang、Vladimir Gevorgyan

  DOI：10.1002/anie.201712775

  日期：2018.3

  A novel mild, visible‐light‐induced palladium‐catalyzed hydrogen atom translocation/atom‐transfer radical cyclization (HAT/ATRC) cascade has been developed. This protocol involves a 1,5‐HAT process of previously unknown hybrid vinyl palladium radical intermediates, thus leading to iodomethyl carbo‐ and heterocyclic structures.

  一种新型温和、可见光诱导的钯催化氢原子易位/原子转移自由基环化（HAT/ATRC）级联已经开发出来。该方案涉及先前未知的杂化乙烯基钯自由基中间体的 1,5-HAT 过程，从而产生碘甲基碳环和杂环结构。
• Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle
  作者：A Choppin、R M Eglen

  DOI：10.1038/sj.bjp.0704165

  日期：2001.8

  The pharmacological characteristics of muscarinic receptors in the male mice urinary bladder smooth muscle were studied. (+)‐Cis‐dioxolane, oxotremorine‐M, acetylcholine, carbachol and pilocarpine induced concentration‐dependent contractions of the urinary bladder smooth muscle (pEC50=6.6±0.1, 6.9±0.1, 6.7±0.1, 5.8±0.1 and 5.8±0.1, EMax=3.2±0.8 g, 2.7±0.4 g, 1.0±0.1 g, 2.7±0.3 and 0.9±0.2 g, respectively, n=4). These contractions were competitively antagonized by a range of muscarinic receptor antagonists (pKB values): atropine (9.22±0.09), pirenzepine (6.85±0.08), 4‐DAMP (8.42±0.14), methoctramine (5.96±0.05), p‐F‐HHSiD (7.48±0.09), tolterodine (8.89±0.13), AQ‐RA 741 (7.04±0.12), s‐secoverine (8.21±0.09), zamifenacin (8.30±0.17) and darifenacin (8.70±0.09). In this tissue, the pKB values correlated most favourably with pKi values for these compounds at human recombinant muscarinic M3 receptors. A significant correlation was also noted at human recombinant muscarinic m5 receptors given the poor discriminative ability of ligands between M3 and m5 receptors. In recontraction studies, in which the muscarinic M3 receptor population was decreased, and conditions optimized to study M2 receptor activation, methoctramine exhibited an affinity estimate consistent with muscarinic M3 receptors (pKB=6.23±0.14; pA2=6.16±0.03). Overall, these data study suggest that muscarinic M3 receptors are the predominant, if not the exclusive, subtype mediating contractile responses to muscarinic agonists in male mouse urinary bladder smooth muscle. British Journal of Pharmacology (2001) 133, 1035–1040; doi:10.1038/sj.bjp.0704165

  以下为将文本翻译成中文后的版本： < Jays 列表列表类型="明确标签"> < Jays 列表项> 雄性小鼠膀胱平滑肌中毒蕈碱受体的药理学特性进行了研究。 < Jays 列表项> (+)‐Cis‐dioxolane, oxotremorine‐M, acetylcholine, carbachol 和 pilocarpine 引起膀胱平滑肌浓度依赖性收缩（pEC < Jays 子> 50 =6.6±0.1, 6.9±0.1, 6.7±0.1, 5.8±0.1 和 5.8±0.1, E < Jays 子> max =3.2±0.8 g, 2.7±0.4 g, 1.0±0.1 g, 2.7±0.3 和 0.9±0.2 g, 分别，n=4）。这些收缩作用被一系列毒蕈碱受体拮抗剂竞争性拮抗（pK < Jays 子> B 值）：atropine（9.22±0.09），pirenzepine（6.85±0.08），4‐DAMP（8.42±0.14），methoctramine（5.96±0.05），p‐F‐HHSiD（7.48±0.09），tolterodine（8.89±0.13），AQ‐RA 741（7.04±0.12），s‐secoverine（8.21±0.09），zamifenacin（8.30±0.17）和 darifenacin（8.70±0.09）。 < Jays 列表项> 在此组织中，pK < Jays 子> B 值与这些化合物在人源重组毒蕈碱 M < Jays 子> 3 受体上的 pK < Jays 子> i 值相关性最好。在人源重组毒蕈碱 m5 受体上也观察到显著相关性，因配体在 M < Jays 子> 3 和 m5 受体之间区分能力有限。 < Jays 列表项> 在重新收缩研究中，毒蕈碱 M < Jays 子> 3 受体群减少，并优化条件以研究 M < Jays 子> 2 受体激活时，methoctramine 的亲和力估计值与毒蕈碱 M < Jays 子> 3 受体一致（pK < Jays 子> B =6.23±0.14；pA < Jays 子> 2 =6.16±0.03）。 < Jays 列表项> 总体而言，这些数据研究表明，毒蕈碱 M < Jays 子> 3 受体是介导雄性小鼠膀胱平滑肌对毒蕈碱激动剂收缩反应的主要亚型，如果不是唯一的。 < Jays 突体> 英国药理学杂志 (2001) < Jays 粗体> 133 , 1035–1040; doi: < Jays 扩展链接 xmlns:xlink="http://www.w3.org/1999/xlink" 扩展链接类型="doi" xlink:href="10.1038/sj.bjp.0704165"> 10.1038/sj.bjp.0704165 希望这段翻译对您有所帮助！